<DOC>
	<DOCNO>NCT02858973</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple ascend dose study Q203 healthy volunteer conduct one study center United States</brief_summary>
	<brief_title>A Dose-Escalation Study Evaluate Safety , Tolerability Pharmacokinetics Multiple Doses Q203 Normal Healthy Male Female Volunteers</brief_title>
	<detailed_description>Three ( 3 ) cohort 8 subject ( 6 active 2 placebo ) plan evaluation . In cohort , subject receive multiple oral dos Q203 placebo 14 day QD standard meal . Subjects participate one cohort . Safety ( i.e. , physical examination , vital sign , ECGs , clinical laboratory test , adverse event [ AEs ] ) assess throughout study ; serial blood urine sample collect assessment . Blood sample also collect PK assessment Q203 . Escalation next dose level ( i.e. , initiation next cohort ) take place Principal Investigator ( PI ) , medical monitor , representative Sponsor review available safety tolerability previous cohort agree initiation next cohort .</detailed_description>
	<criteria>1 . Understands study procedure inform consent form ( ICF ) , willing able comply protocol . 2 . Healthy adult male and/or female ( nonchildbearing potential ) , 19 55 year age , inclusive , screen . 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical psychiatric condition disease opinion PI . 3 . History illness , opinion PI , might confound result study pose additional risk subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>